Literature DB >> 16636095

Prevention of exacerbations: how are we doing and can we do better?

P Sherwood Burge1.   

Abstract

Prevention of exacerbations of chronic obstructive pulmonary disease (COPD) can involve removing the cause or reducing the patient's vulnerability to the cause. This article addresses the following issues: What is the problem during an exacerbation, what are the causes of an exacerbation, what can prevent exacerbations, and who are we? The difference between a patient with COPD during an exacerbation and after recovery is small. It is unlikely that patients with early COPD experience less exposure to exacerbation causes than those with severe disease; it is just that the consequences are more severe for those with severe disease. Interventions that produce small absolute benefits can therefore have a disproportionately large effect on exacerbation reduction. Recognized causes include season, cold weather, pollution events, bacterial infection, viral infection, and treatment withdrawal. Countries with warmer climates have much larger mortality in cold weather than those with colder climates. Reducing exacerbations in more temperate climates may be altered as much by changes in clothing and bedroom heating as by changes in treatment. Taking more exercise in cold weather may be the underlying reason for the reduction of exacerbations after pulmonary rehabilitation. Influenza vaccination reduces influenza severity and reduces transmission from health care workers to patients. There are a number of pharmacologic interventions shown to reduce (the effect of) exacerbations, including inhaled corticosteroids, long-acting beta-agonists, long-acting anticholinergics, mucolytics, and perhaps antibiotics that reduce Haemophilus carriage. The effect of the bronchodilators is additive to inhaled corticosteroids; how far the other interventions are complementary is unclear. So far, we have had a very medical response to COPD exacerbations. Altering social and behavioral aspects is likely to be complementary.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16636095     DOI: 10.1513/pats.200511-117SF

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  8 in total

1.  Who is more vulnerable to death from extremely cold temperatures? A case-only approach in Hong Kong with a temperate climate.

Authors:  Hong Qiu; Linwei Tian; Kin-fai Ho; Ignatius T S Yu; Thuan-Quoc Thach; Chit-Ming Wong
Journal:  Int J Biometeorol       Date:  2015-09-14       Impact factor: 3.787

2.  Influence of air pressure, humidity, solar radiation, temperature, and wind speed on ambulatory visits due to chronic obstructive pulmonary disease in Bavaria, Germany.

Authors:  Uta Ferrari; Teresa Exner; Eva R Wanka; Christoph Bergemann; Julian Meyer-Arnek; Beate Hildenbrand; Amanda Tufman; Christian Heumann; Rudolf M Huber; Michael Bittner; Rainald Fischer
Journal:  Int J Biometeorol       Date:  2011-02-08       Impact factor: 3.787

3.  Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter.

Authors:  Amy L Olson; Jeffrey J Swigris; Ganesh Raghu; Kevin K Brown
Journal:  Chest       Date:  2008-08-08       Impact factor: 9.410

4.  Analysis of the bacterial community in chronic obstructive pulmonary disease sputum samples by denaturing gradient gel electrophoresis and real-time PCR.

Authors:  Dachang Wu; Chenxia Hou; Yanxia Li; Zinan Zhao; Jianjun Liu; Xin Lu; Xueqi Shang; Yi Xin
Journal:  BMC Pulm Med       Date:  2014-11-18       Impact factor: 3.317

Review 5.  Prevention of COPD exacerbations: medications and other controversies.

Authors:  Jørgen Vestbo; Peter Lange
Journal:  ERJ Open Res       Date:  2015-05-06

6.  Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial.

Authors:  Heinrich Worth; Christian Schacher; Uwe Dethlefsen
Journal:  Respir Res       Date:  2009-07-22

7.  Warm homes for older people: aims and methods of a randomised community-based trial for people with COPD.

Authors:  Helen Viggers; Philippa Howden-Chapman; Tristram Ingham; Ralph Chapman; Gina Pene; Cheryl Davies; Ann Currie; Nevil Pierse; Helen Wilson; Jane Zhang; Michael Baker; Julian Crane
Journal:  BMC Public Health       Date:  2013-02-26       Impact factor: 3.295

8.  Explaining the increased health care expenditures associated with gastroesophageal reflux disease among elderly Medicare beneficiaries with chronic obstructive pulmonary disease: a cost-decomposition analysis.

Authors:  Mayank Ajmera; Amit D Raval; Chan Shen; Usha Sambamoorthi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-04-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.